Investor Alert

New York Markets Close in:

May 20, 2020, 11:22 a.m. EDT

Warm Autoimmune Hemolytic Anemia (wAIHA) Market Insights, Epidemiological Analysis, and Emerging Therapies – 2030

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

May 20, 2020 (AB Digital via COMTEX) -- DelveInsight's 'Warm Autoimmune Hemolytic Anemia (wAIHA) - Market Insights, Epidemiology and Market Forecast-2028 ’ report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of WAIHA.

Geography Covered

  • The United States

  • EU5 (Germany, France, Italy, Spain and the United Kingdom)

  • Japan

Study Period: 2017-2028

Warm autoimmune hemolytic anemia (wAIHA) is the most common form of autoimmune hemolytic anemia. Autoimmune Ahemolytic anemia (AIHA) is a rare acquired autoimmune disease, as a consequence of which the immune system attacks its red blood cells considering them foreign substances.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Warm Autoimmune Hemolytic Anemia (wAIHA) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practise/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market.

Click to know more about the report

Warm autoimmune hemolytic anemia Epidemiology

In 2017, as per the estimates by DelveInsight, Warm Autoimmune Haemolytic Anemia had affected 82,045 people approximately in the 7MM.

WAIHA affects 1 in 35,000 in North America. With a population of about 57 crores, WAIHA is a cause of distress to many living in that continent only, let alone worldwide.

The Warm Autoimmune Hemolytic Anemia (wAIHA) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

wAIHA Epidemiology Segmentation

  • Total prevalent cases of wAIHA

  • Total prevalent cases of wAIHA

  • Type-specific prevalent cases of wAIHA

  • Gender-specific prevalent cases of wAIHA

Warm Autoimmune Hemolytic Anemia Market Outlook

The Warm Autoimmune Hemolytic Anemia market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analysing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

The Warm autoimmune hemolytic anemia treatment landscape includes corticosteroids, splenectomy and conventional immunosuppressive drugs to keep the patient clinically comfortable and to prevent "hemolytic crises" with the use of medical interventions with the lowest possible short- and long-term side effects.

Visit to know more.

Warm Autoimmune Hemolytic Anemia Pipeline

Some of the key pharma players in the Warm autoimmune hemolytic anemia market are Rigel, Apellis Pharmaceuticals, Momenta Pharmaceuticals, Immunovant, Alexion and others are expected to launch their candidates in the WAIHA market in the coming decade.

Warm autoimmune hemolytic anemia market comprises a strong pipeline including fostamatinib (Rigel Pharmaceuticals), APL-2 (Apellis Pharmaceuticals, Inc.), M281 (Momenta Pharmaceuticals), ALXN1830 (Alexion Pharmaceuticals), IMVT-1401 (Immunovant) and others are anticipated to impact the WAIHA market positively.

However, DelveInsight analysts estimate that fostamatinib – a candidate of Rigel - will significantly occupy the Warm autoimmune hemolytic anemia market share for the forecast period (2019-2028).

This segment gives a thorough the detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Request for sample pages from here.

Warm Autoimmune Hemolytic Anemia Report Insights

1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.